The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit
later.
We apologize for any inconvenience caused
Pemetrexed versus docetaxel in non-small cell lung cancer
Author(s): LI Ya-fang, WANG Yong, Department of Respiratory Medicine, Shangyu People’s Hospital, Clinical Laboratory, Shangyu People’s Hospital
Pages: 1227-
1229
Year: 2019
Issue:
12
Journal: The Chinese Journal of Clinical Pharmacology
Keyword: pemetrexed; cisplatin; non-small cell lung cancer; thioredoxin-interacting protein; neoadjuvant chemotherapy;
Abstract: Objective To investigate the clinical efficacy and safety profile of pemetrexed/docetaxel in combination with cisplatin neoadjuvant chemotherapy in non-small cell lung cancer(NSCLC) patients.Methods A total of 60 patients with NSCLC were assigned to treatment group(n = 33) and control group(n = 27) according to different chemotherapy regimens.Control group received intravenous drip of docetaxel(75 mg·m-2,Day 1) combined with cisplatin(25 mg·m-2,Day 1-3); Treatment group received intravenous drip of pemetrexed(500 mg·m-2,Day 1) combined with cisplatin(25 mg·m-2,Day 1-3);Both groups were treated for 2 cycles(a cycle = 21 days,with 1 week interval between each chemotherapy cycle).The clinical efficacy,expression of thioredoxin binding protein(TXNIP) and adverse drug reactions were compared between 2 groups.Results The median progression-free survival time were 7.2 months and 4.9 months in treatment group and control group, respectively, with significant difference(P < 0.05).There were statistically significant differences in the relative expression of TXNIP between the lung tissue of treatment group and control group(1.12 ± 0.01 vs 0.32 ± 0.01)(P < 0.01).There were statistically significance between the two groups in main adverse drug reactions,including eucopenia,hemoglobin reduction,thrombocytopenia,nausea and vomiting,rash,and liver function damage(P < 0.05).Conclusion Pemetrexed in combination with cisplatin exerted considerable clinical efficacy and safety profile in the treatment of NSCLC by increasing the expression of TXNIP in lung tissue.
Citations
No citation found